A study published in The Lancet has shown promising results for the experimental COVID-19 vaccine, BBIBP-CorV. This inactivate vaccine is being developed by the Beijing Institute of Biological Products, which is a subsidiary of China National Biotec Group (CNBG).
More than 600 adults in China received the vaccine as part of Phase 1 and 2 trials from late April to late July. The researchers found that the vaccine stimulated an immune response and had no severe side effects. The vaccine currently is undergoing larger Phase 3 studies.